A phase I dose escalation study of ad GV.EGR.TNF.11D (TNFeradeTMM Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation

T. Y. Seiwert, T. Darg, D. Haraf, E. A. Blair, K. Stenson, E. E.W. Cohen, J. K. Salama, V. Villaflor, M. E. Witt, M. W. Lingen, R. R. Weichselbaum, E. E. Vokes

Research output: Contribution to journalArticle

Abstract

Background: AdGV.EGR.TNF.11D (TNFeradeTMM Biologic) is a replication-deficient adenoviral vector expressing human tumor necrosis factor alpha (TNF-α) under the control of the chemoradiation-inducible EGR-1 promoter. TNF-α has been shown to function as a radiation sensitizer. We conducted a phase I dose escalation study to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of TNFeradeTMM Biologic, when added to chemoradiotherapy in poor prognosis patients with recurrent, previously irradiated head and neck cancer (HNC). Methods: TNFeradeTMM Biologic was injected intratumorally on day 1 of each 14-day cycle and dose-escalated in log increments from 4 × 109 to 4 × 1011 PU. Daily radiation, infusional 5-fluorouracil (5-FU), and hydroxyurea were given on days 1-5 for seven cycles (FHX). Tumor biopsies were obtained before, during, and after treatment. Results: Fourteen patients were treated. DLT was reached at a dose level of 3 (4 × 1011 PU) with three thrombotic events. The response rate was 83.3%. The median survival was 9.6 months. One patient (7.1%) remained alive 3 years after treatment. Biopsies were obtained in 90% of patients. Nearly all tumors expressed adenovirus receptors, TNF-α, and TNF-α receptors. Adenoviral DNA was detected in three biopsies from one patient. Conclusions: TNFeradeTMM Biologic can be safely integrated with FHX chemoradiotherapy at an MTD of 4 × 1010 PU. Monitoring for thrombotic events is indicated.

Original languageEnglish (US)
Article numbermds523
Pages (from-to)769-776
Number of pages8
JournalAnnals of Oncology
Volume24
Issue number3
DOIs
StatePublished - Mar 1 2013
Externally publishedYes

Keywords

  • Chemoradiation
  • Gene therapy
  • Head and neck cancer
  • Recurrent disease
  • Translational research

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'A phase I dose escalation study of ad GV.EGR.TNF.11D (TNFerade<sup>TMM</sup> Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation'. Together they form a unique fingerprint.

  • Cite this

    Seiwert, T. Y., Darg, T., Haraf, D., Blair, E. A., Stenson, K., Cohen, E. E. W., Salama, J. K., Villaflor, V., Witt, M. E., Lingen, M. W., Weichselbaum, R. R., & Vokes, E. E. (2013). A phase I dose escalation study of ad GV.EGR.TNF.11D (TNFeradeTMM Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Annals of Oncology, 24(3), 769-776. [mds523]. https://doi.org/10.1093/annonc/mds523